Ironwood Pharmaceuticals Stock Math Transform Inverse Tangent Over Price Movement
| IRWD Stock | USD 3.61 -0.07 -1.90% |
| Symbol |
Transformation |
Ironwood Pharmaceuticals Technical Analysis Modules
Most technical analysis of Ironwood Pharmaceuticals help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Ironwood from various momentum indicators to cycle indicators. When you analyze Ironwood charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Ironwood Pharmaceuticals Inc
Methodology
Unless otherwise specified, financial data for Ironwood Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Ironwood (USA Stocks:IRWD) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Ironwood Pharmaceuticals is covered by 4 analysts. 2 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Goldman Sachs, Jefferies, Bank of America Securities, Morgan Stanley, Barclays, among others. Updates may occur throughout the day.
Ironwood Stock is Curated By:
Vlad Skutelnik ยท Macroaxis ContributorTrending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Investor Favorites Invested over 20 shares | |
 | Hedge Favorites Invested over 40 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Advertising Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Adviser Favorites Invested few shares | |
 | Cash Cows Invested few shares | |
 | Marketing Invested few shares | |
 | Power Assets Invested over 200 shares |
More Resources for Ironwood Stock Analysis
A structured review of Ironwood Pharmaceuticals often starts with core financial statements and trend context. Ratios and trend metrics help frame Ironwood Pharmaceuticals' operating context. Selected reports below provide context for Ironwood Stock: Quarterly Earnings Growth 10.468 | Earnings Share 0.15 | Revenue Per Share | Quarterly Revenue Growth -0.47 | Return On Assets |